Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68\%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10\% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13\% (95\% CI 0-26\%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40\%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36\%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7\%), of neutropenia in 9 out of 188 cycles (4.7\%) and of thrombocytopenia in 3 out of 188 cycles (1.5\%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer.